Oric Pharmaceuticals (ORIC) Institutional Ownership

95.05% of Oric Pharmaceuticals' stock is owned by institutional investors. Learn more on ORIC's institutional investor holdings.

Of the 148 institutional investors that purchased Oric Pharmaceuticals' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: BlackRock Inc. ($6.82M), Orbimed Advisors LLC ($2.94M), Paradigm Biocapital Advisors LP ($2.40M), Siren L.L.C. ($1.99M), State Street Corp ($1.85M), Vivo Capital LLC ($1.85M), and MPM Bioimpact LLC ($1.80M).

Institutional investors have bought a total of 36,308,937 shares in the last 24 months. This purchase volume represents approximately $373.94M in transactions.

Of the 25 institutional investors that sold Oric Pharmaceuticals' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Vivo Capital LLC ($1.28M), JPMorgan Chase & Co. ($1.03M), Orbimed Advisors LLC ($947.83K), Balyasny Asset Management L.P. ($827.53K), Integral Health Asset Management LLC ($350K), Sectoral Asset Management Inc. ($306.18K), and Millennium Management LLC ($253.10K).

Institutional investors have sold a total of 6,039,514 shares in the last 24 months. This volume of shares sold represents approximately $62.11M in transactions.